PMID- 15880405
OWN - NLM
STAT- MEDLINE
DCOM- 20060317
LR  - 20061115
IS  - 0733-2459 (Print)
IS  - 0733-2459 (Linking)
VI  - 20
IP  - 4
DP  - 2005 Dec
TI  - LDL-apheresis improves peripheral arterial occlusive disease with an implication 
      for anti-inflammatory effects.
PG  - 239-43
AB  - Although it is known that LDL-apheresis improves ischemic limb seen in patients 
      with peripheral arterial occlusive disease (PAOD), anti-inflammatory effects are 
      not well known. We studied whether or not serum or plasma levels of high 
      sensitivity C-reactive protein (hsCRP), monocyte chemoatractant protein-1 
      (MCP-1), or fibrinogen could contribute to favorable effects for ischemic limbs 
      after LDL-apheresis. Twenty-eight patients with PAOD (24 men, 4 women) were 
      enrolled in our study. LDL-apheresis was performed 10 times (treated plasma of 
      3,000 ml) for 5 weeks. Serum levels of logarithmically transformed values of 
      hsCRP significantly decreased from 3.666 +/- 0.126 to 3.482 +/- 0.139 ng/ml 
      before and after a single session of LDL-apheresis (P < 0.001). Serum levels of 
      MCP-1 decreased from 233 +/- 17.5 to 187 +/- 13.5 pg/ml before and after 
      LDL-apheresis (P < 0.05). Likewise, plasma fibrinogen levels statistically 
      decreased from 196 +/- 9.82 to 159 +/- 9.60 mg/dl (P < 0.001). Overall rates of 
      improvement including foot chillness or numbness, and double folds increase in 
      walking distance were 82.1% 3 months after a completion of LDL-apheresis, while 
      gangrene was only improved 14.3%. Intermittent claudication improved in 53.6%. 
      The favorable actions of LDL-apheresis might include anti-inflammatory effects. 
      To avoid amputation, LDL-apheresis should be applied for patients with PAOD at an 
      early stage of the disease process and may be applicable for patients with 
      atherosclerotic cardiovascular disorders.
CI  - (c) 2005 Wiley-Liss, Inc.
FAU - Kobayashi, Shuzo
AU  - Kobayashi S
AD  - Department of Nephrology, Kidney & Dialysis Center, Shonan Kamakura General 
      Hospital, Yamazaki Kamakura, Japan. shuzo@shonankamakura.or.jp
FAU - Moriya, Hidekazkeu
AU  - Moriya H
FAU - Maesato, Kyouko
AU  - Maesato K
FAU - Okamoto, Kouji
AU  - Okamoto K
FAU - Ohtake, Takayasu
AU  - Ohtake T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Apher
JT  - Journal of clinical apheresis
JID - 8216305
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Lipoproteins, LDL)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Arteriosclerosis/blood/*therapy
MH  - C-Reactive Protein/analysis
MH  - Chemokine CCL2/blood
MH  - Female
MH  - Fibrinogen/analysis
MH  - *Hemofiltration
MH  - Humans
MH  - Inflammation/blood
MH  - Ischemia/blood/therapy
MH  - *Lipoproteins, LDL
MH  - Male
MH  - Middle Aged
MH  - Peripheral Vascular Diseases/blood/*therapy
EDAT- 2005/05/10 09:00
MHDA- 2006/03/18 09:00
CRDT- 2005/05/10 09:00
PHST- 2005/05/10 09:00 [pubmed]
PHST- 2006/03/18 09:00 [medline]
PHST- 2005/05/10 09:00 [entrez]
AID - 10.1002/jca.20033 [doi]
PST - ppublish
SO  - J Clin Apher. 2005 Dec;20(4):239-43. doi: 10.1002/jca.20033.